10 Best-Selling Cancer Drugs by Estimated Global Sales (2025-2026)

10 Best-Selling Cancer Drugs by Estimated Global Sales (2025-2026)

Oncology is printing money. There is no other therapy area in global pharma that even comes close to the numbers being put up by cancer drugs right now. In 2025 and 2026, blockbuster oncology drugs are crossing $30B+ in annual global sales, a number that would have seemed absurd a decade ago.

The shift has been dramatic. Immunotherapy, targeted therapy, and biologics have completely redefined how cancer is treated and, frankly, how pharmaceutical companies make their money. Old-school chemo? Still around. But it is being overshadowed by precision medicines that are being designed to work smarter, not just harder.

If you are trying to understand the best-selling cancer drugs of 2025, track the top oncology drugs by revenue, or simply want to know where the blockbuster cancer drugs global sales are concentrated, this is your list. Below, the top 10 are ranked by estimated global sales for 2025-2026.

Quick Snapshot: Top 10 Cancer Drugs by Global Sales (2025-2026)

Here is the lay of the land, the global cancer drug market leaders, ranked by estimated revenue:

Top-Selling Oncology Drugs Driving Global Pharma Revenue (2025-2026)

Which cancer drug sells the most? Keytruda — and it is not close. But the entire list below is worth understanding if you are doing any kind of oncology market intelligence, sourcing, or investment work.

1. Keytruda (Pembrolizumab) - Merck | $31B+

Keytruda is the number one best-selling cancer drug on the planet. Full stop. It is a PD-1 inhibitor — a type of immunotherapy that essentially takes the brakes off your immune system so it can attack tumor cells.

Merck's dominance across melanoma, lung cancer, and a growing list of solid tumors has been built over years of smart clinical investment. The $31B+ revenue figure is not a fluke — it is the result of Keytruda being approved across more than 40 indications. No other oncology asset is even in the same zip code.

2. Darzalex (Daratumumab) - Johnson & Johnson | $13B+

Multiple myeloma has been completely transformed by Darzalex. It is a CD38 monoclonal antibody, and it has been stacked into combination regimens that have become the standard of care. Strong growth is being driven by both newly diagnosed and relapsed/refractory settings. J&J has positioned this asset well, and the $13B+ in revenue reflects that.

3. Opdivo (Nivolumab) - Bristol Myers Squibb | $9B+

Opdivo was one of the early immunotherapy pioneers, and it is still standing. BMS's PD-1 inhibitor competes directly with Keytruda across a broad set of oncology indications — lung, kidney, bladder, and more. While it has been outpaced by Keytruda in the race for market share, $9B+ in annual revenue means Opdivo is very much a major force in the blockbuster oncology drugs list.

4. Tagrisso (Osimertinib) - AstraZeneca | $7B+

Tagrisso is the gold standard for EGFR-mutated non-small cell lung cancer. It is a targeted therapy — third-generation EGFR inhibitor — and it has earned strong adoption in the first-line setting after landmark trial data. AstraZeneca has done an excellent job extending this asset, and the $7B+ figure reflects a drug that is genuinely practice-changing.

5. Imfinzi (Durvalumab) - AstraZeneca | $6B+

Another AstraZeneca entry, Imfinzi is a PD-L1 checkpoint inhibitor that has carved out a key role in lung cancer maintenance therapy. It has been approved in both non-small cell and small cell lung cancer settings. The $6B+ in estimated sales is being supported by label expansions and growing international adoption.

6. Verzenio (Abemaciclib) - Eli Lilly | $5B+

The CDK4/6 inhibitor class has been one of the most important developments in breast cancer, and Verzenio is one of its stars. Revenue growth has been driven by its adjuvant indication — that is, use in early-stage breast cancer after surgery — which opened up a massive new patient population. Eli Lilly has executed well here.

7. Kisqali (Ribociclib) - Novartis | $4.5B+

Kisqali competes in the same CDK4/6 inhibitor class as Verzenio and Ibrance. What sets it apart is compelling survival data that has been shown in multiple trials. That data is being noticed, and adoption is being accelerated because of it. The $4.5B+ figure reflects a drug that is gaining ground.

8. Tecentriq (Atezolizumab) - Roche | $4B+

Roche's PD-L1 checkpoint inhibitor has been deployed across lung and liver cancers. Tecentriq has faced some headwinds with label withdrawals in certain settings, but the $4B+ in estimated revenue shows it has retained meaningful market presence in its approved indications.

9. Ibrance (Palbociclib) - Pfizer | $3.8B+

Ibrance was the first-in-class CDK4/6 inhibitor, it basically created the category. It is still being widely used in breast cancer despite increasing competition from Verzenio and Kisqali. The $3.8B+ in revenue reflects a drug that is holding on through the power of familiarity and long clinical track record.

10. Perjeta (Pertuzumab) - Roche | $3.5B+

Perjeta is a HER2-targeted therapy that is almost always used in combination with Herceptin (trastuzumab). Together, the two drugs form a backbone of HER2-positive breast cancer treatment. The combination approach has proven highly effective, and Roche's investment in this space has paid off to the tune of $3.5B+ annually.

How Clival Database Enables Oncology Market Intelligence?

The numbers above are not just impressive headlines, they represent a rapidly shifting competitive landscape. If your team is doing oncology market intelligence, commercial due diligence, or pharma sourcing, you need more than a top-10 list. You need data.

Clival Database is built for exactly that. Drug-level sales trends are tracked across the global oncology market, so you can see how revenue is shifting between assets, classes, and companies. Pipeline competition and biosimilar pressure are analysed, critical as several of these blockbusters approach patent cliffs. API suppliers and manufacturers are identified, giving your procurement and business development teams a real edge. And patent expiries and lifecycle management strategies are monitored, so you never get caught off guard by a market shift.

Whether you are benchmarking a drug pipeline database for pharma investment or trying to find API supplier intelligence for cancer drugs, Clival is the oncology market intelligence platform built to make that work faster and more defensible.

Conclusion

Oncology remains the highest revenue-generating therapy area in global pharma — and the gap between it and everything else keeps widening. Immunotherapy and targeted therapies are dominating the top of the list, and that trend is not slowing down.

At the same time, the pressure is building. Biosimilars are coming for the older assets. Next-generation therapies, ADCs, bispecifics, cell therapies, are entering the mix. The competitive dynamics are getting more complex every year.

That is exactly why data-driven sourcing and intelligence is becoming essential, not optional. The teams that win in oncology over the next decade will be the ones who can see the market clearly, and move accordingly. Clival Database exists to help you do that.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!